JCR Pharmaceuticals Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Ashiya Japan (1975)
Status: No NME R&D (1975)

Organization Overview

First Clinical Trial
2016
NCT02912533
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

JCR Pharmaceuticals Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (3)

darbepoetin alfa (aranesp) (2 trials)

idursulfase (elaprase) (1 trial)

jr-141 (7 trials)

Drugs in Phase 2 Trials (3)

Key: JCR Pharmaceuticals Co., Ltd. (2) Acquired (1)

agt-181 (4 trials)

jr-441 (1 trial)

Laronidase (Aldurazyme) (2 trials)

Drugs in Phase 1 Trials (1)

Key: JCR Pharmaceuticals Co., Ltd. (0) Acquired (1)

agt-182 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis I (Phase 2)

Mucopolysaccharidosis II (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 7